See more : Avensia AB (publ) (AVEN.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Psyence Group Inc. (PSYGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psyence Group Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Synthesis Energy Systems, Inc. (SYNE) Income Statement Analysis – Financial Results
- Envela Corporation (ELA) Income Statement Analysis – Financial Results
- Lionheart Acquisition Corporation II (LCAPW) Income Statement Analysis – Financial Results
- Beyond, Inc. (BYON) Income Statement Analysis – Financial Results
- I-Sheng Electric Wire & Cable Co., Ltd. (6115.TW) Income Statement Analysis – Financial Results
Psyence Group Inc. (PSYGF)
About Psyence Group Inc.
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.93K | 92.27K | 52.64K | 24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97.93K | -92.27K | -52.64K | -24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.58M | 2.30M | 115.94K | 21.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.43M | 3.32M | 4.19M | 92.51K | 19.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 152.16K | 253.62K | 146.62K | 131.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.58M | 3.58M | 4.34M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Other Expenses | 0.00 | 5.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Cost & Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Interest Income | 3.57K | 7.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 72.63K | 123.14K | 1.39K | 1.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.93K | 92.27K | 52.64K | 24.50K | 206.30K | 171.86K | 161.14K | 52.52K | 22.82K |
| EBITDA | -5.17M | -5.88M | -4.46M | -3.80M | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.16M | -6.09M | -4.59M | -92.51K | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.28M | -208.35K | -145.07K | -13.45M | 0.00 | 32.50K | 4.00 | 4.00 | -46.00 |
| Income Before Tax | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.18K | -83.90K | -8.12M | -206.29K | -171.86K | -161.14K | -52.52K | -22.82K |
| Net Income | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| EPS Diluted | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| Weighted Avg Shares Out | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
| Weighted Avg Shares Out (Dil) | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate,...
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is excited to announce the completion of its subsidiary Psyence Biomedical...
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company. The Business Combination will list Psyence...
Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd ("Pubco"), has...
Psyence Group Announces Resignation of Board Member
TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing announced today that Mr. Marvin Singer has resigned...
Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition...
Psyence Production Expands Capability
TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence...
Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common...
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a...
Psyence Group Corporate Update
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in Australia Psyence granted worldwide licensing agreement to commercialize Filament's PEX010 (25 mg) in palliative care with exclusivity in key markets Successful completion of exports of medical grade psilocybin mushrooms...
Source: https://incomestatements.info
Category: Stock Reports